The impact of spread through air spaces on intrapulmonary metastasis in lung cancer: a retrospective study of multiple primary lung adenocarcinomas with confirmed common origin based on histological classification alone and combined histological-molecular classification

肺癌肺内转移中,肿瘤细胞经气腔扩散的影响:一项基于组织学分类和组织学-分子分类相结合的回顾性研究,探讨多原发性肺腺癌的共同起源。

阅读:1

Abstract

BACKGROUND: Distinguishing multiple primary lung adenocarcinomas (MPLAs) from intrapulmonary metastases (IPMs) is essential for accurate staging and treatment planning. However, existing histologic and molecular criteria remain limited in diagnostic accuracy. Spread through air spaces (STAS) has been recognized as a marker of tumor aggressiveness, but its role in differentiating MPLA from IPM remains unclear. This study aimed to assess whether STAS can serve as a supportive marker to differentiate IPM from MPLA under both histologic and molecular frameworks. METHODS: We retrospectively enrolled 170 patients who were preoperatively diagnosed with MPLA and underwent surgical resection of multiple lung lesions. Clinical, histopathologic, and molecular data-including broad-panel next-generation sequencing (NGS) results [e.g., epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), tumor protein p53 (TP53), among others]-were collected. Tumors were classified as MPLA or IPM using histologic criteria alone and a combined histologic-molecular algorithm. The presence and quantity of STAS were evaluated and analyzed as potential predictors of IPM. RESULTS: STAS was more frequent in the IPM group across both classification methods and was an independent predictor of IPM. Driver gene mutations (e.g., EGFR, KRAS) differed significantly between MPLA and IPM. The 83.5% concordance between histologic and combined classifications suggests potential bias in histology alone. In resource-limited settings, STAS may offer a cost-effective adjunct to support IPM diagnosis when molecular data are unavailable. CONCLUSIONS: STAS is associated with IPM and may serve as a supportive diagnostic marker when distinguishing IPM from MPLA. In resource-limited settings where molecular testing is not always available, STAS may offer a practical, cost-effective histologic adjunct to guide clinical decision-making.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。